Figure 4.
Posterior probability of surviving at least 30 days as a function of standardized HCoV-OC43 spike IgG antibody level, by sex and time to plasma administration in females who received CCP ≤3 days (A), females who received CCP >3 days (B), males who received CCP ≤3 days (C), and males who received CCP >3 days (D) from COVID-19 diagnosis.